The global market for Oncolytic Virus Therapy was estimated at US$13.8 Million in 2024 and is projected to reach US$45.2 Million by 2030, growing at a CAGR of 21.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Oncolytic Virus Therapy market.
Clinical and preclinical interest in OVT has surged following the regulatory approval of Imlygic (Talimogene laherparepvec or T-VEC), an HSV-1 based therapy for advanced melanoma. Since then, a growing pipeline of OVT candidates based on adenoviruses, reoviruses, vaccinia, measles, and coxsackieviruses is being evaluated across various cancer indications, including glioblastoma, pancreatic, colorectal, and lung cancers. Advances in synthetic biology, tumor-targeting ligands, and immune-modulatory gene insertion are further enhancing the specificity and potency of oncolytic viruses, making them ideal combination partners with immune checkpoint inhibitors, CAR-T cells, and radiotherapy.
A key trend in the field is the engineering of OVs to express transgenes that encode for cytokines (GM-CSF, IL-12), immune checkpoint inhibitors, or tumor-associated antigens, creating multi-functional virotherapies with enhanced immunogenicity. These next-generation platforms are not only increasing response rates but also improving tumor-specific selectivity, reducing systemic toxicity, and enabling personalized medicine strategies. As the regulatory environment becomes more supportive and trial designs more adaptive, OVT is increasingly seen as a cornerstone of next-wave immunotherapy pipelines.
Moreover, gene editing tools such as CRISPR-Cas9 are being used to fine-tune viral genomes for better safety, tumor tropism, and payload control. Companies are developing modular OVT platforms capable of rapid design and testing of virus variants with optimized replication kinetics, immune activation, and vector stability. Additionally, AI-driven drug design and digital pathology are improving patient stratification and predictive biomarker discovery, enabling more targeted and effective use of OVT in precision oncology.
Additionally, regulatory momentum is building, with fast-track and orphan designations being granted for OVTs in hard-to-treat cancers. Government-backed cancer moonshot programs and academic-industry collaborations are accelerating trial activity, particularly in North America, Europe, and East Asia. The convergence of immune-oncology, virology, and synthetic biology is opening avenues for OVT in both first-line and refractory settings, offering new hope for patients with limited options.
As delivery systems improve, clinical data matures, and commercial infrastructure strengthens, oncolytic virus therapy is poised to evolve from a niche experimental modality into a mainstream cancer treatment. With its unique ability to combine localized tumor destruction and systemic immune stimulation, OVT holds the potential to redefine therapeutic paradigms in oncology.
Global Oncolytic Virus Therapy Market - Key Trends & Drivers Summarized
Could Engineered Viruses Become the Next Frontier in Cancer Immunotherapy?
Oncolytic virus therapy (OVT) represents a cutting-edge approach to cancer treatment that harnesses genetically engineered or naturally occurring viruses to selectively infect and destroy cancer cells while sparing normal tissues. Once inside the tumor, these viruses replicate, induce immunogenic cell death, and stimulate systemic anti-tumor immune responses effectively turning the tumor into its own vaccine. This dual mechanism of action direct oncolysis and immune activation positions OVT as a promising bridge between targeted therapy and immunotherapy, with applications in solid tumors and hematologic malignancies.Clinical and preclinical interest in OVT has surged following the regulatory approval of Imlygic (Talimogene laherparepvec or T-VEC), an HSV-1 based therapy for advanced melanoma. Since then, a growing pipeline of OVT candidates based on adenoviruses, reoviruses, vaccinia, measles, and coxsackieviruses is being evaluated across various cancer indications, including glioblastoma, pancreatic, colorectal, and lung cancers. Advances in synthetic biology, tumor-targeting ligands, and immune-modulatory gene insertion are further enhancing the specificity and potency of oncolytic viruses, making them ideal combination partners with immune checkpoint inhibitors, CAR-T cells, and radiotherapy.
Why Is Combination Therapy Strategy Transforming the Clinical Landscape?
Monotherapy with oncolytic viruses has shown modest efficacy in some tumor types; however, their greatest therapeutic potential is being realized in combination with other immuno-oncology (IO) agents. OVTs can reprogram the tumor microenvironment (TME), overcome immune exclusion, and improve T-cell infiltration creating a synergistic effect when used alongside PD-1/PD-L1 checkpoint inhibitors. Multiple trials are currently underway to evaluate OVT in combination with anti-CTLA-4, CAR-NK therapies, cytokine therapies, and bispecific antibodies, especially in immunologically “cold” tumors that are resistant to existing IO regimens.A key trend in the field is the engineering of OVs to express transgenes that encode for cytokines (GM-CSF, IL-12), immune checkpoint inhibitors, or tumor-associated antigens, creating multi-functional virotherapies with enhanced immunogenicity. These next-generation platforms are not only increasing response rates but also improving tumor-specific selectivity, reducing systemic toxicity, and enabling personalized medicine strategies. As the regulatory environment becomes more supportive and trial designs more adaptive, OVT is increasingly seen as a cornerstone of next-wave immunotherapy pipelines.
How Are Technological Innovations and Delivery Platforms Expanding Market Reach?
One of the major challenges in OVT development has been efficient delivery and immune evasion. Intratumoral injection, while effective for accessible lesions, limits broader applicability. Recent advances in systemic delivery methods including virus shielding, carrier cell-based delivery (e.g., mesenchymal stem cells), and nanoparticle encapsulation are helping overcome the barriers of neutralizing antibodies and organ-specific sequestration. These delivery strategies aim to extend OVT to metastatic and deep-seated tumors.Moreover, gene editing tools such as CRISPR-Cas9 are being used to fine-tune viral genomes for better safety, tumor tropism, and payload control. Companies are developing modular OVT platforms capable of rapid design and testing of virus variants with optimized replication kinetics, immune activation, and vector stability. Additionally, AI-driven drug design and digital pathology are improving patient stratification and predictive biomarker discovery, enabling more targeted and effective use of OVT in precision oncology.
What's Fueling the Growth of the Oncolytic Virus Therapy Market?
The growth in the oncolytic virus therapy market is driven by rising cancer incidence, increasing resistance to conventional therapies, and expanding clinical validation of OVT mechanisms. A primary growth driver is the intensifying investment by biotech companies, pharmaceutical giants, and research consortia focused on next-generation immunotherapies. Strategic partnerships, licensing deals, and venture capital funding are pouring into companies developing OVT platforms, including Replimune, Oncolytics Biotech, SillaJen, CG Oncology, and Lokon Pharma.Additionally, regulatory momentum is building, with fast-track and orphan designations being granted for OVTs in hard-to-treat cancers. Government-backed cancer moonshot programs and academic-industry collaborations are accelerating trial activity, particularly in North America, Europe, and East Asia. The convergence of immune-oncology, virology, and synthetic biology is opening avenues for OVT in both first-line and refractory settings, offering new hope for patients with limited options.
As delivery systems improve, clinical data matures, and commercial infrastructure strengthens, oncolytic virus therapy is poised to evolve from a niche experimental modality into a mainstream cancer treatment. With its unique ability to combine localized tumor destruction and systemic immune stimulation, OVT holds the potential to redefine therapeutic paradigms in oncology.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Herpes Simplex Virus segment, which is expected to reach US$11.8 Million by 2030 with a CAGR of a 20.8%. The Adenovirus segment is also set to grow at 19.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $3.8 Million in 2024, and China, forecasted to grow at an impressive 29.0% CAGR to reach $10.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Oncolytic Virus Therapy Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Oncolytic Virus Therapy Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Oncolytic Virus Therapy Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Akamis Bio, Amgen Inc., Calidi Biotherapeutics, Candel Therapeutics, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 36 companies featured in this Oncolytic Virus Therapy market report include:
- Akamis Bio
- Amgen Inc.
- Calidi Biotherapeutics
- Candel Therapeutics
- CG Oncology
- Genelux Corporation
- Imugene Limited
- Lokon Pharma AB
- Oncolys BioPharma Inc.
- Oncolytics Biotech Inc.
- Replimune Group Inc.
- SillaJen, Inc.
- Theolytics Ltd.
- Theriva Biologics
- TILT Biotherapeutics Ltd.
- Transgene S.A.
- Turnstone Biologics Corp.
- Valo Therapeutics Ltd.
- VCN Biosciences S.L.
- Vyriad, Inc.
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akamis Bio
- Amgen Inc.
- Calidi Biotherapeutics
- Candel Therapeutics
- CG Oncology
- Genelux Corporation
- Imugene Limited
- Lokon Pharma AB
- Oncolys BioPharma Inc.
- Oncolytics Biotech Inc.
- Replimune Group Inc.
- SillaJen, Inc.
- Theolytics Ltd.
- Theriva Biologics
- TILT Biotherapeutics Ltd.
- Transgene S.A.
- Turnstone Biologics Corp.
- Valo Therapeutics Ltd.
- VCN Biosciences S.L.
- Vyriad, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 483 |
| Published | June 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 13.8 Million |
| Forecasted Market Value ( USD | $ 45.2 Million |
| Compound Annual Growth Rate | 21.8% |
| Regions Covered | Global |
